login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
GRACE THERAPEUTICS INC (GRCE) Stock News
USA
-
Nasdaq
- NASDAQ:GRCE -
US00439U1043
-
Common Stock
3.1913
USD
+0.01 (+0.36%)
Last: 12/1/2025, 12:06:42 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
GRCE Latest News, Press Relases and Analysis
All
Press Releases
18 days ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
20 days ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
2 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
3 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
3 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
4 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
5 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
5 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
6 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics to Participate in the 2025 BIO International Conference
8 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
9 months ago - By: Matinas BioPharma Holdings, Inc.
- Mentions:
NYSE
ONVO
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
10 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
10 months ago - By: Benzinga
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
10 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
10 months ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
a year ago - By: Grace Therapeutics, Inc.
Grace Therapeutics to Participate in Upcoming Investor Events January 2025
a year ago - By: Grace Therapeutics, Inc.
Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference
a year ago - By: Grace Therapeutics, Inc.
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update
Please enable JavaScript to continue using this application.